

# Francesca Mancini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9214437/publications.pdf>

Version: 2024-02-01

44  
papers

2,666  
citations

236833

25  
h-index

254106

43  
g-index

44  
all docs

44  
docs citations

44  
times ranked

2539  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease. <i>Neurological Sciences</i> , 2022, 43, 3187-3193.	0.9	1
2	Compensating for verbal-motor deficits in neuropsychological assessment in movement disorders: sensitivity and specificity of the ECAS in Parkinsonâ€™s and Huntingtonâ€™s diseases. <i>Neurological Sciences</i> , 2021, 42, 4997-5006.	0.9	5
3	Personalized care management for persons with Parkinson's disease: A telenursing solution. <i>Clinical Parkinsonism &amp; Related Disorders</i> , 2020, 3, 100070.	0.5	5
4	The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinsonâ€™s disease patients. <i>Journal of Neural Transmission</i> , 2020, 127, 881-891.	1.4	8
5	Upper Limb Interactive Weightless Technology-Aided Intervention and Assessment Picks Out Motor Skills Improvement in Parkinson's Disease: A Pilot Study. <i>Frontiers in Neurology</i> , 2020, 11, 40.	1.1	3
6	Telemedicine for parkinsonism: A two-step model based on the COVID-19 experience in Milan, Italy. <i>Parkinsonism and Related Disorders</i> , 2020, 75, 130-132.	1.1	30
7	A Novel Approach for Investigating Parkinsonâ€™s Disease Personality and Its Association With Clinical and Psychological Aspects. <i>Frontiers in Psychology</i> , 2019, 10, 2265.	1.1	2
8	Motor and non-motor outcomes in patients with advanced Parkinsonâ€™s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study. <i>Journal of Neurology</i> , 2019, 266, 2164-2176.	1.8	42
9	The association of cognitive reserve with motor and cognitive functions for different stages of Parkinson's disease. <i>Experimental Gerontology</i> , 2019, 115, 79-87.	1.2	22
10	Real life evaluation of safinamide effectiveness in Parkinsonâ€™s disease. <i>Neurological Sciences</i> , 2018, 39, 733-739.	0.9	22
11	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. <i>Parkinsonism and Related Disorders</i> , 2017, 38, 90-92.	1.1	44
12	Delayed Gastric Emptying in Advanced Parkinson Disease. <i>Clinical Nuclear Medicine</i> , 2017, 42, 83-87.	0.7	35
13	Gastroesophageal dysmotility in advanced Parkinson's Disease. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e46.	1.1	0
14	Motor outcomes in patients with advanced Parkinsonâ€™s disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study. <i>Neurological Sciences</i> , 2016, 37, 1785-1792.	0.9	23
15	Levodopaâ€™carbidopa intrajejunal gel in advanced Parkinson disease with âœonâœ-freezing of gait. <i>Neurological Sciences</i> , 2015, 36, 1683-1686.	0.9	25
16	Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 27-31.	1.1	73
17	Peripheral nervous system involvement in Parkinson's disease: Evidence and controversies. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1329-1334.	1.1	64
18	Effect and safety of duodenal levodopa infusion in advanced Parkinsonâ€™s disease: a retrospective multicenter outcome assessment in patient routine care. <i>Journal of Neural Transmission</i> , 2013, 120, 1553-1558.	1.4	59

#	ARTICLE	IF	CITATIONS
19	Deep brain stimulation and cognition in Parkinson's disease: An eight-year follow-up study. <i>Movement Disorders</i> , 2012, 27, 1192-1194.	2.2	22
20	Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 464-468.	2.2	139
21	Hemorrhagic and Repositioning Risk Factors Related to Intraoperative Multitrack Microrecording on a Large Series of Patients Treated for Deep Brain Stimulation. <i>Neurosurgery Quarterly</i> , 2011, 21, 194-198.	0.1	1
22	Clinical Experiences With Levodopa Methylester (Melevodopa) in Patients With Parkinson Disease Experiencing Motor Fluctuations. <i>Clinical Neuropharmacology</i> , 2010, 33, 61-66.	0.2	14
23	Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders. <i>Functional Neurology</i> , 2010, 25, 21-5.	1.3	9
24	Electrode displacement after intracerebral hematoma as a complication of a deep brain stimulation procedure. <i>Neuropsychiatric Disease and Treatment</i> , 2009, 5, 183.	1.0	10
25	Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. <i>Movement Disorders</i> , 2009, 24, 1468-1474.	2.2	233
26	Deep brain stimulation and cognitive functions in Parkinson's disease: A three-year controlled study. <i>Movement Disorders</i> , 2009, 24, 1621-1628.	2.2	113
27	Duodenal Levodopa Infusion Improves Quality of Life in Advanced Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2008, 5, 244-246.	0.8	93
28	Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. <i>Movement Disorders</i> , 2007, 22, 1145-1149.	2.2	241
29	REM sleep behavior disorder, hallucinations, and cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 462-466.	2.2	118
30	Botulinum toxin and neuromotor rehabilitation: An integrated approach to idiopathic cervical dystonia. <i>Movement Disorders</i> , 2006, 21, 2240-2243.	2.2	103
31	Secondary cervical dystonia in iatrogenic hypoparathyroidism associated with extensive brain calcifications. <i>Functional Neurology</i> , 2006, 21, 165-6.	1.3	8
32	Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 1439-1448.	2.2	219
33	A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. <i>Neurological Sciences</i> , 2005, 26, 26-31.	0.9	125
34	Dopamine agonists and sleepiness in PD: review of the literature and personal findings. <i>Sleep Medicine</i> , 2004, 5, 189-193.	0.8	39
35	Long-Term Evaluation of the Effect of Quetiapine on Hallucinations, Delusions and Motor Function in Advanced Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2004, 27, 33-37.	0.2	27
36	A questionnaire on sleep and mental disorders in Parkinson's disease (QSMDDP): development and application of a new screening tool. <i>Functional Neurology</i> , 2004, 19, 83-99.	1.3	11

#	ARTICLE	IF	CITATIONS
37	Sleep attacks in Parkinson's disease: a clinical and polysomnographic study. <i>Neurological Sciences</i> , 2003, 24, 195-196.	0.9	13
38	Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. <i>Movement Disorders</i> , 2003, 18, 685-688.	2.2	198
39	High-Dose Ropinirole in Advanced Parkinson's Disease With Severe Dyskinesias. <i>Clinical Neuropharmacology</i> , 2003, 26, 146-150.	0.2	37
40	Reproductive life milestones in women with Parkinson's disease. <i>Functional Neurology</i> , 2003, 18, 211-7.	1.3	11
41	Active Music Therapy in Parkinson's Disease: An Integrative Method for Motor and Emotional Rehabilitation. <i>Psychosomatic Medicine</i> , 2000, 62, 386-393.	1.3	282
42	Botulinum toxin treatment for functional disability induced by essential tremor. <i>Neurological Sciences</i> , 2000, 21, 349-353.	0.9	45
43	Peripheral markers of oxidative stress in Parkinson's disease. the role of L-DOPA. <i>Free Radical Biology and Medicine</i> , 1999, 27, 428-437.	1.3	44
44	Is seborrhea a sign of autonomic impairment in Parkinson's disease?. <i>Journal of Neural Transmission</i> , 1997, 104, 1295-1304.	1.4	48